MammaPrint®

As shown by the landmark MINDACT trial, the majority of women with early-stage breast cancer have a low risk of cancer recurrence according to MammaPrint and see no significant benefit in adding chemotherapy treatment. Watch our video to learn why Precision Matters when it comes to personalizing treatment management approaches. ### Visit Agendia.com for more information.

1.Cardoso F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375:717-29.